A0A2I2YDK8 (A0A2I2YDK8_GORGO) Gorilla gorilla gorilla (Western lowland gorilla)

Bromodomain-containing protein 2 UniProtKBInterProInteractive Modelling

801 aa; Sequence (Fasta) ; 1 identical sequence: Homo sapiens: P25440

Available Structures

163 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
BRD2-BD1 in complex with cyclic peptide 2.2B Heteromer
P25440;
72-187
100GOL;
Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi… Heteromer
P02309; P25440;
73-186
100
Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi… Heteromer
P02309; P25440;
73-186
100
Solution structures of Brd2 second bromodomain in complex with stat3 peptide Heteromer
P25440; P40763;
344-455
100
Structure of human BRD2-BD1 bound to a histone H4 acetyl-methyllysine peptide Heteromer
P25440; P62805;
76-183
100
Crystal structure of the human Brd2 second bromodomain in complexed with the acetylated histone H4 … Heteromer
P02309; P25440;
348-455
100
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13120homo-6-mer346-455
100JGR;EDO;PEG;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13157homo-4-mer345-455
100JFL;GOL; 15×FMT;
Crystal Structure of the second bromodomain of human BRD2 BD2 in complex with the inhibitor Y13195homo-4-mer345-454
100A1L0Y; 10×FMT;GOL;EDO;NA;PEG;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13153homo-4-mer345-454
100JFR;DMS;PEG;GOL;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor 22homo-4-mer345-454
100XHN;
Crystal structure of BRD2(BD1)with ligand ZB-BD-224 boundhomo-3-mer74-187
100HFU;
N-Terminal Bromodomain of Human BRD2 With IBET-151homo-2-mer72-189
100ACT;GOL;1GH;
Crystal Structure of the human BRD2 BD1 bromodomain in complex with a Tetrahydroquinoline analoguehomo-2-mer73-187
100G7V;SO4;EDO;03S;
N-Terminal bromodomain of Human BRD2 with a Tetrahydroquinoline analoguehomo-2-mer72-186
100SO4;G3J;EPE;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5 ethyl-3-methyl-4-phenyl-1, 2-oxazolehomo-2-mer74-188
100EDO;A9O;SO4;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopropyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylb…homo-2-mer72-186
100EDO;A9N;SO4;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-onehomo-2-mer72-186
100P9I;SO4;EDO;
Crystal structure analysis of the N-terminal bromodomain of human Brd2homo-2-mer73-186
100DTT;
N-Terminal Bromodomain of Human BRD2 With tbutyl-phenyl-amino- dimethyl-oxazolyl-quinoline-carboxyl…homo-2-mer73-186
100EDO;S5B;SO4;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-methyl-1,2,3,4- tetrahydroquinazolin-2-onehomo-2-mer73-186
1003PF;EDO;SO4;
BRD2_Bromodomain1 complex with inhibitor 744homo-2-mer73-186
100EDO;HWV;
Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GSK525762 (IBET)homo-2-mer74-187
100EAM;
Crystal structure analysis of the N-terminal bromodomain of human BRD2 complexed with acetylated hi…homo-2-mer73-186
100
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-cyclopentyl-5-(3,5- dimethyl-1,2-oxazol-4-yl)-2-methylb…homo-2-mer73-186
100P9M;SO4;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(4-(4-fluorophenyl)-1H-imidazol-5-yl)-1-methylpyridin-2…homo-2-mer73-186
100SO4;NUQ;EDO;
N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]i…homo-2-mer73-185
100SO4;NUH;EDO;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13142homo-2-mer344-455
100JGL;EDO;K;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-onehomo-2-mer75-186
100EDO;TVP;SO4;
crystal structure of BRD2-BD1 in complex with guanosine analoghomo-2-mer75-186
100AC2;DTT;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-METHYLPYRROLIDIN-2-ONEhomo-2-mer75-185
100MB3;SO4;EDO;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13158homo-2-mer345-454
100JGU;EDO;PEG;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3,5 dimethyl-4-phenyl-1,2- oxazolehomo-2-mer75-183
100EDO;A9P;SO4;
crystal structure of BRD2-BD1 in complex with purine derivativehomo-2-mer75-183
1007UH;SO4;
crystal structure of BRD2-BD1 in complex with purine derivativehomo-2-mer74-182
10037T;SO4;
Crystal structure of BRD2(BD2) mutant W370F in the free formhomo-2-mer347-454
99.07NI;2PE;GOL;
Discovery and the crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2.homo-2-mer75-182
100BUX;SO4;DTT;GOL;DMS;PGE;
Crystal structure of BRD2(BD1)with ligand BY27 boundhomo-2-mer76-183
100CQF;MES;
Crystal structure of pyrano 1,3, oxazine derivative in complex with the second bromodomain of BRD2homo-2-mer348-455
100PGE;BUX;
crystal structure of NS5 in complex with the N-terminal bromodomain of BRD2 (BRD2-BD1).homo-2-mer75-182
100BUX;SO4;
crystal structure of BRD2-BD1 in complex with purine derivativehomo-2-mer75-182
100TEP;SO4;
crystal structure of BRD2-BD1 in complex with purine derivativehomo-2-mer75-182
1007UM;EPE;SO4;
crystal structure of BRD2-BD2 in complex with purine derivativehomo-2-mer348-454
100TEP;
crystal structure of BRD2-BD2 in complex with purine derivativehomo-2-mer348-454
99.067UM;GOL;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(4-hydroxyphenyl) acetamidehomo-2-mer77-182
100EDO;TYL;SO4;
Crystal Structure of the First Bromodomain of Human Brd2 with the inhibitor GW841819Xhomo-2-mer77-181
100WSH;SO4;
BRD2-BD2 in complex with the cyclic peptide 4.2_3homo-2-mer351-454
100
Solution structure of the Extraterminal (ET) Domain of BRD2monomer621-750
100
BRD2-BD1 in complex with the cyclic peptide 3.2_2monomer65-190
100IOD;GOL;NH2;PE3;
BRD2-BD1 in complex with the cyclic peptide 4.2_3monomer65-190
100
Crystal structure of the N-terminus D161Y bromodomain mutant of human BRD2monomer71-190
99.17EDO;ACT;
Crystal structure of the first bromodomain (BD1) of human BRD2 bound to volasertibmonomer73-192
100IBI;
N-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A)monomer71-189
99.16EDO;73B;SO4;
BRD2-BD1 in complex with the cyclic peptide 3.1_3monomer70-187
100ZN;
CRYSTAL STRUCTURE OF THE HUMAN BRD2 BD1 BROMODOMAIN IN COMPLEX WITH 9-(cyclopropylmethyl)-7-[(2R,6S…monomer73-190
100YW1;EDO;
Crystal structure of the N-terminus Y153H bromodomain mutant of human BRD2monomer71-187
99.14EDO;
N-terminal bromodomain of human BRD2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxa…monomer74-187
100JWD;
N-terminal bromodomain of human BRD2 in complex with N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)qui…monomer74-187
100JVY;
N-terminal bromodomain of human BRD2 with N-((4-(3-(N-cyclopentylsulfamoyl)-4-methylphenyl)-3-methy…monomer74-187
100JWA;
Crystal structure of the human BRD2 BD1 bromodomain in complex with a BRD2-interactive compound, BI…monomer73-186
100BYH;MES;
X-ray crystal structure of bromodomain 2 of human brd2 in complex with rvx208 to 1.08 A resolutionmonomer344-455
1001K0;EDO;
Human Brd2(BD2) mutant in free formmonomer344-455
99.119JB;CL;DQW;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-N5-cyclopropyl-N3-methyl-2-oxo-1-(1-phenylethyl)-1,2-…monomer344-455
100.0EDO;ULH;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH oxabicyclo(hexan-6-yl)-N2-methyl-6-((S)-1-phenylethyl)pyr…monomer344-455
100EDO;PE4;ULN;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-3-(1H-indol…monomer344-455
100EDO;V9Q;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxo-1-(tetrahydro-2H-py…monomer344-455
10080Z;EDO;PE4;
Crystal structure of BRD2(BD2) mutant in free formmonomer344-455
99.11ACT;GOL;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK973monomer344-455
100EDO;1PG;QC8;
Human BRD2 C-terminal bromodomain with (S)-1-(2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-6-(1,2,3,6-…monomer344-455
100EDO;D7B;PEG;MES;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK620monomer344-455
100EDO;QCZ;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 3-(2-(benzyloxy)phenyl)-5-methyl-1H-1,2,4-triazolemonomer344-455
100EDO;PE4;ULB;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-((S)-hydroxy(phenyl)methyl)-N2-methyl-N4-((1S,2S)-2-met…monomer344-455
100EDO;ULK;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,5-dimethyl-N-(2-(methylamino)-2-oxoethyl)-6-oxo-N-(2-ph…monomer344-455
100EDO;PE4;VBE;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-benzyl-4-chloro-1H-imidazol-2-yl)-1,3-dimethylpyridi…monomer344-455
100EDO;PE4;A1IBV;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-6-((S)-meth…monomer344-455
100EDO;ULQ;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (R)-7-((R)-1,2-dihydroxyethyl)-1,3-dimethyl-5-(1-methyl-1…monomer344-455
100EDO;7PE;P4X;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-…monomer344-455
100EDO;PE4;P3R;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD2 (GSK046)monomer344-455
100EDO;LW5;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-1,3-dimethyl-1,3-dihydro-2H-benzo[d]azepin-…monomer344-455
100EDO;PE4;P0U;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2-(1H-imidazol-4-yl)ethyl)-4-acetamido-3-(benzyloxy)be…monomer344-455
100PEG;EDO;QB5;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N-methyl-2-oxo-1,2-dihydropyridine-3-carboxamidemonomer344-455
100EDO;QCW;MES;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1,3-dimethyl-5-(1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-b…monomer344-455
100NUB;MES;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-methyl-4-propionyl-1H-pyrrole-2-carboxamidemonomer344-455
100EDO;PE4;V9B;
Human BRD2 C-terminal bromodomain with (S)-5-(1-acetyl-2-cyclopropyl-4-(2-(hydroxymethyl)benzyl)-1,…monomer344-455
100EDO;MES;D7H;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(1-pheny…monomer344-455
100EDO;UL8;
Crystal structure of BRD2(BD2) mutant with ligand ET bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)…monomer344-455
99.11GOL;2PE;31P;NI;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor Y13146monomer344-455
100JGF;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-6-(1-phenyleth…monomer344-455
100UME;EDO;PEG;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-N4-cyclopropyl-N2-methyl-6-(1-phenylethyl)pyridine-2,…monomer344-455
100ULE;EDO;
Human Brd2(BD2) mutant in complex with MEmonomer344-455
99.1131O;CL;DQW;
Human BRD2 C-terminal bromodomain with 2-((4-acetyl-3-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)me…monomer344-455
100PEG;EDO;D7Q;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]i…monomer344-455
100EDO;PE4;NV2;
Crystal structure of the second bromodomain (BD2) of human BRD2 bound to LRRK2-IN-1monomer344-455
100BU1;4K4;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH GSK549monomer344-455
100EDO;QD5;PEG;
Human Brd2(BD2) mutant in complex with AL-tBumonomer344-454
99.19HN;CL;DQW;
Crystal structure of the BRD2-BD2 in complex with a ligandmonomer344-454
100EDO;QJ1;
X-ray crystal structure of human BRD2(BD2) in complex with RVX297 to 1.55 A resolutionmonomer345-455
1005GD;
Human Brd2(BD2) mutant in complex with 9-Memonomer345-455
99.19J2;CL;DQW;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 6-benzyl-N2-methyl-N4-((1S,2S)-2-methylcyclopropyl)pyridi…monomer345-455
100UL5;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N5-cyclopropyl-N3-methyl-1H-pyrazole-3,5-dicarbo…monomer345-455
100EDO;VE5;PEG;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-ethyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-4-(pyridin-2-y…monomer345-455
100EDO;UM5;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)…monomer345-455
100UM8;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 7,8-dimethoxy-3-methyl-1,3-dihydro-2H-benzo[d]azepin-2-onemonomer345-455
100EDO;P4M;MES;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N4-hydroxycyclohexyl-N2-methyl-5-phenylethyl-furan-2,4-di…monomer345-455
100V9K;EDO;
BRD2-BD1 in complex with MDP5monomer73-183
100O6O;PEG;EDO;DMS;CL;NA;
Crystal structure of the second bromodomain (BD2) of human BRD2 bound to BI2536monomer346-455
100EDO;R78;CL;
Crystal structure of BRD2 second bromodomain in complex with SGC-CBP30 chemical probemonomer346-455
100EDO;2LO;
Crystal structure of the second bromodomain (BD2) of human BRD2 bound to bromosporinemonomer346-455
100BMF;EDO;SO4;
Human Brd2(BD2) L383V mutant in complex with ET-JQ1-OMemonomer345-454
99.09PMW;PXN;
Human Brd2(BD2) mutant in complex with 9-ETmonomer345-454
99.099J5;CL;DQW;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH iBET-BD1 (GSK778)monomer346-455
100LWB;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-hydroxycyclohexyl-N3-methyl-1-phenylethyl-1H-pyrazole-…monomer346-455
100V9H;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N-(2,2-diphenylethyl)-1,5-dimethyl-N-(2-(methylamino)-2-o…monomer346-455
100VBH;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 2-benzyl-N-cyclopropyl-6-(1-methyl-1H-1,2,3-triazol-4-yl)…monomer346-455
100UMB;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH rac-N5-((1R,5S)-3-oxabicyclo[3.1.0]hexan-6-yl)-N7,3-dimet…monomer346-455
100V9N;EDO;
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH (S)-5-(1-((1-acetylpiperidin-3-yl)methyl)-5-bromo-1H-benz…monomer346-455
100EDO;MES;I0U;
Crystal Structure of the second bromodomain of human BRD2 in complex with the inhibitor JQ1monomer346-455
100JQ1;NI;EDO;
Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (R…monomer346-455
100EDO;DMS;1K0;
Crystal Structure of the second bromodomain of human BRD2 in complex with a quinazolinone ligand (R…monomer346-455
100EDO;DMS;1K0;
Human Brd2(BD2) mutant in complex with ET-Am1monomer346-455
99.099HT;CL;DQW;
Crystal structure of BRD2(BD2) mutant with ligand ME bound (METHYL (2R)- 2-[(4S)-6-(4-CHLOROPHENYL)…monomer346-455
99.0931O;2PE;NI;GOL;
Human Brd2(BD2) mutant in complex with AL-Am1monomer346-455
99.099J8;
Crystal structure of the second bromodomain (BD2) of human BRD2 bound to Ro3280monomer346-455
10079C;CL;
C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-…monomer346-454
100JW4;GOL;
Human Brd2(BD2) mutant in complex with 9-ME-Am1monomer346-454
99.089HQ;CL;DQW;
Human Brd2(BD2) mutant in complex with Me-Am1monomer346-454
99.089HW;CL;DQW;
Crystal structure of the second bromodomain Q443H mutant of human BRD2monomer346-454
99.08
BRD2-BD2 in complex with the cyclic peptide 3.1_3monomer347-455
100
Crystal structure of BRD2(BD2) W370F mutant with ligand I-BET 762 boundmonomer346-454
99.08GOL;2PE;EAM;NI;
Bromodomain-containing 2 BD2 in complex with the inhibitor CRCM5484monomer346-454
1008M6;EDO;
Peptide 2.2E in complex with BRD2-BD2monomer347-455
100ACE;NH2;
N-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-((2R,4S)-2-methyl-4-(phenylamino)-6-(4-(piperidin-1-ylm…monomer75-183
1009S3;
BRD2-BD2 in complex with a diacetylated-H2A.Z peptidemonomer347-455
100
X-ray crystal structure of 1,2,3-triazolobenzodiazepine in complex with BRD2(D2)monomer347-455
1007WY;EDO;
Crystal structure of the N-terminus R100L bromodomain mutant of human BRD2monomer75-183
99.08EDO;
Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline ana…monomer346-454
100SO4;EDO;8J2;
C-Terminal bromodomain of Human BRD2 with I-BET726 (GSK1324726A)monomer347-455
10073B;SO4;
Ultra high resolution crystal structure of the apo- form of second bromodomain of BRD2.monomer348-455
100CL;GOL;PGE;
Second bromodomain of Human BRD2 with a Tetrahydroquinoline analoguemonomer348-455
100EDO;G3J;
Crystal Structure of the human BRD2 BD2 bromodimain in complex with a Tetrahydroquinoline analoguemonomer348-455
100G7V;EDO;
Crystal Structure of the second bromodomain of BRD2 in complex with RT53monomer348-455
100H7B;EDO;
BRD2-BD2 in complex with MDP5monomer348-455
100O6O;EDO;NA;
Crystal structure of BRD2(BD2)with ligand BY27 boundmonomer347-454
100CQF;
BRD2-BD2 in complex with SF2523monomer348-455
10082V;EDO;
Crystal structure of the BRD2-BD2 in complex with phenanthridinonemonomer348-455
100GOL;2ME;LDR;
Crystal Structure of the second bromodomain of human BRD2 in complex with the compound 3bmonomer348-455
100EDO;YA3;
Crystal structure analysis of the second bromodomain of BRD2 covalently linked to b-mercaptoethanolmonomer348-455
100PGE;GOL;
Crystal structure of BRD2(BD2) W370F mutant with ligand 28 boundmonomer347-454
99.0759E;GOL;
Crystal structure of Phenanthredinone moiety in complex with the second bromodomain of BRD2 (BRD2-B…monomer348-455
100LDR;PGE;
Crystal Structure of the second bromodomain of BRD2 in complex with RT56monomer348-455
100MES;EDO;H7E;
Crystal structure of the second bromodomain of the human Brd2 proteinmonomer348-455
100EPE;
BRD2 Bromodomain2 with A-1360579monomer347-454
10087D;
Human Brd2(BD2) mutant in complex with ALmonomer347-454
99.079HZ;
Crystal Structure of BRD2(BD2)with Ligand ZB-BD-224 boundmonomer348-455
100.0HFU;
Human Brd2(BD2) mutant in complex with ETmonomer347-454
99.0731P;
Solution structure of a Bromodomain from RING3 proteinmonomer348-455
99.07
Ultra-high resolution crystal structure of second bromodomain of BRD2 in complex with inhibitor 6B3monomer348-454
100CL;GOL;6B3;
crystal structure of BRD2-BD2 in complex with purine derivativemonomer348-454
99.0637T;GOL;
crystal structure of BRD2-BD2 in complex with purine derivativemonomer348-454
1007UH;GOL;
crystal structure of BRD2-BD2 in complex with guanosine analogmonomer348-454
98.13AC2;
BRD2_Bromodomain2 complex with pyrrolopyridone compound 27monomer348-454
100QYY;
Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline inh…monomer348-454
1005P4;
BRD2_Bromodomain2 complex with inhibitor 744monomer348-454
100HWV;

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8ov6.1.Cmonomer0.5576-454
62.92